|
|
| | 1,2-Propanediol, 3-[4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methylphenoxy]- Basic information |
| | 1,2-Propanediol, 3-[4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methylphenoxy]- Chemical Properties |
| Boiling point | 606.8±55.0 °C(Predicted) | | density | 1.078±0.06 g/cm3(Predicted) | | pka | 13.55±0.20(Predicted) |
| | 1,2-Propanediol, 3-[4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methylphenoxy]- Usage And Synthesis |
| Description | LG190178 is a vitamin D receptor (VDR) ligand that is a therapeutic agent for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism. | | Uses | LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer[1]. | | in vitro | LG190178 is a novel non-secosteroidal ligand for VDR._x000D_
_x000D_
Reference: Bioorg Med Chem Lett. 2008 Jan 1;18(1):120-3. https://pubmed.ncbi.nlm.nih.gov/18054230/ | | target | LG190178 is a vitamin D receptor (VDR) ligand that is a therapeutic agent for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism. | | References | [1] Perakyla, et al. Gene regulatory potential of nonsteroidal vitamin D receptor ligands. Molecular endocrinology 19.8 (2005): 2060-2073. DOI:10.1210/me.2004-0417 |
| | 1,2-Propanediol, 3-[4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methylphenoxy]- Preparation Products And Raw materials |
|